A single dose of any of four different live attenuated tetravalent dengue vaccines is safe and immunogenic in flavivirus-naive adults: A randomized, double-blind clinical trial

Anna P Durbin, Beth D. Kirkpatrick, Kristen K. Pierce, Daniel Elwood, Catherine J. Larsson, Janet C. Lindow, Cecilia Tibery, Beulah Perdue Sabundayo, Donna Shaffer, Kawsar Rasmy Talaat, Noreen A Hynes, Kimberli Wanionek, Marya P. Carmolli, Catherine J. Luke, Brian R. Murphy, Kanta Subbarao, Stephen S. Whitehead

Research output: Contribution to journalArticle

Abstract

Background. Dengue virus (DENV) causes hundreds of millions of infections annually. Four dengue serotypes exist, and previous infection with one serotype increases the likelihood of severe disease with a second, heterotypic DENV infection.Methods. In a randomized, placebo-controlled study, the safety and immunogenicity of 4 different admixtures of a live attenuated tetravalent (LATV) dengue vaccine were evaluated in 113 flavivirus-naive adults. Serum neutralizing antibody levels to all 4 dengue viruses were measured on days 0, 28, 42, and 180.Results. A single dose of each LATV admixture induced a trivalent or better neutralizing antibody response in 75%-90% of vaccinees. There was no significant difference in the incidence of adverse events between vaccinees and placebo-recipients other than rash. A trivalent or better response correlated with rash and with non-black race (P

Original languageEnglish (US)
Pages (from-to)957-965
Number of pages9
JournalJournal of Infectious Diseases
Volume207
Issue number6
DOIs
StatePublished - 2013

Fingerprint

Dengue Vaccines
Flavivirus
Dengue Virus
Clinical Trials
Exanthema
Neutralizing Antibodies
Placebos
Dengue
Virus Diseases
Infection
Antibody Formation
Safety
Incidence
Serum
Serogroup

Keywords

  • clinical trial
  • dengue vaccine
  • live attenuated tetravalent

ASJC Scopus subject areas

  • Infectious Diseases
  • Immunology and Allergy

Cite this

A single dose of any of four different live attenuated tetravalent dengue vaccines is safe and immunogenic in flavivirus-naive adults : A randomized, double-blind clinical trial. / Durbin, Anna P; Kirkpatrick, Beth D.; Pierce, Kristen K.; Elwood, Daniel; Larsson, Catherine J.; Lindow, Janet C.; Tibery, Cecilia; Sabundayo, Beulah Perdue; Shaffer, Donna; Talaat, Kawsar Rasmy; Hynes, Noreen A; Wanionek, Kimberli; Carmolli, Marya P.; Luke, Catherine J.; Murphy, Brian R.; Subbarao, Kanta; Whitehead, Stephen S.

In: Journal of Infectious Diseases, Vol. 207, No. 6, 2013, p. 957-965.

Research output: Contribution to journalArticle

Durbin, AP, Kirkpatrick, BD, Pierce, KK, Elwood, D, Larsson, CJ, Lindow, JC, Tibery, C, Sabundayo, BP, Shaffer, D, Talaat, KR, Hynes, NA, Wanionek, K, Carmolli, MP, Luke, CJ, Murphy, BR, Subbarao, K & Whitehead, SS 2013, 'A single dose of any of four different live attenuated tetravalent dengue vaccines is safe and immunogenic in flavivirus-naive adults: A randomized, double-blind clinical trial', Journal of Infectious Diseases, vol. 207, no. 6, pp. 957-965. https://doi.org/10.1093/infdis/jis936
Durbin, Anna P ; Kirkpatrick, Beth D. ; Pierce, Kristen K. ; Elwood, Daniel ; Larsson, Catherine J. ; Lindow, Janet C. ; Tibery, Cecilia ; Sabundayo, Beulah Perdue ; Shaffer, Donna ; Talaat, Kawsar Rasmy ; Hynes, Noreen A ; Wanionek, Kimberli ; Carmolli, Marya P. ; Luke, Catherine J. ; Murphy, Brian R. ; Subbarao, Kanta ; Whitehead, Stephen S. / A single dose of any of four different live attenuated tetravalent dengue vaccines is safe and immunogenic in flavivirus-naive adults : A randomized, double-blind clinical trial. In: Journal of Infectious Diseases. 2013 ; Vol. 207, No. 6. pp. 957-965.
@article{d502f7ed4c8d459b840b8f8ebcd6da2d,
title = "A single dose of any of four different live attenuated tetravalent dengue vaccines is safe and immunogenic in flavivirus-naive adults: A randomized, double-blind clinical trial",
abstract = "Background. Dengue virus (DENV) causes hundreds of millions of infections annually. Four dengue serotypes exist, and previous infection with one serotype increases the likelihood of severe disease with a second, heterotypic DENV infection.Methods. In a randomized, placebo-controlled study, the safety and immunogenicity of 4 different admixtures of a live attenuated tetravalent (LATV) dengue vaccine were evaluated in 113 flavivirus-naive adults. Serum neutralizing antibody levels to all 4 dengue viruses were measured on days 0, 28, 42, and 180.Results. A single dose of each LATV admixture induced a trivalent or better neutralizing antibody response in 75{\%}-90{\%} of vaccinees. There was no significant difference in the incidence of adverse events between vaccinees and placebo-recipients other than rash. A trivalent or better response correlated with rash and with non-black race (P",
keywords = "clinical trial, dengue vaccine, live attenuated tetravalent",
author = "Durbin, {Anna P} and Kirkpatrick, {Beth D.} and Pierce, {Kristen K.} and Daniel Elwood and Larsson, {Catherine J.} and Lindow, {Janet C.} and Cecilia Tibery and Sabundayo, {Beulah Perdue} and Donna Shaffer and Talaat, {Kawsar Rasmy} and Hynes, {Noreen A} and Kimberli Wanionek and Carmolli, {Marya P.} and Luke, {Catherine J.} and Murphy, {Brian R.} and Kanta Subbarao and Whitehead, {Stephen S.}",
year = "2013",
doi = "10.1093/infdis/jis936",
language = "English (US)",
volume = "207",
pages = "957--965",
journal = "Journal of Infectious Diseases",
issn = "0022-1899",
publisher = "Oxford University Press",
number = "6",

}

TY - JOUR

T1 - A single dose of any of four different live attenuated tetravalent dengue vaccines is safe and immunogenic in flavivirus-naive adults

T2 - A randomized, double-blind clinical trial

AU - Durbin, Anna P

AU - Kirkpatrick, Beth D.

AU - Pierce, Kristen K.

AU - Elwood, Daniel

AU - Larsson, Catherine J.

AU - Lindow, Janet C.

AU - Tibery, Cecilia

AU - Sabundayo, Beulah Perdue

AU - Shaffer, Donna

AU - Talaat, Kawsar Rasmy

AU - Hynes, Noreen A

AU - Wanionek, Kimberli

AU - Carmolli, Marya P.

AU - Luke, Catherine J.

AU - Murphy, Brian R.

AU - Subbarao, Kanta

AU - Whitehead, Stephen S.

PY - 2013

Y1 - 2013

N2 - Background. Dengue virus (DENV) causes hundreds of millions of infections annually. Four dengue serotypes exist, and previous infection with one serotype increases the likelihood of severe disease with a second, heterotypic DENV infection.Methods. In a randomized, placebo-controlled study, the safety and immunogenicity of 4 different admixtures of a live attenuated tetravalent (LATV) dengue vaccine were evaluated in 113 flavivirus-naive adults. Serum neutralizing antibody levels to all 4 dengue viruses were measured on days 0, 28, 42, and 180.Results. A single dose of each LATV admixture induced a trivalent or better neutralizing antibody response in 75%-90% of vaccinees. There was no significant difference in the incidence of adverse events between vaccinees and placebo-recipients other than rash. A trivalent or better response correlated with rash and with non-black race (P

AB - Background. Dengue virus (DENV) causes hundreds of millions of infections annually. Four dengue serotypes exist, and previous infection with one serotype increases the likelihood of severe disease with a second, heterotypic DENV infection.Methods. In a randomized, placebo-controlled study, the safety and immunogenicity of 4 different admixtures of a live attenuated tetravalent (LATV) dengue vaccine were evaluated in 113 flavivirus-naive adults. Serum neutralizing antibody levels to all 4 dengue viruses were measured on days 0, 28, 42, and 180.Results. A single dose of each LATV admixture induced a trivalent or better neutralizing antibody response in 75%-90% of vaccinees. There was no significant difference in the incidence of adverse events between vaccinees and placebo-recipients other than rash. A trivalent or better response correlated with rash and with non-black race (P

KW - clinical trial

KW - dengue vaccine

KW - live attenuated tetravalent

UR - http://www.scopus.com/inward/record.url?scp=84874264885&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84874264885&partnerID=8YFLogxK

U2 - 10.1093/infdis/jis936

DO - 10.1093/infdis/jis936

M3 - Article

C2 - 23329850

AN - SCOPUS:84874264885

VL - 207

SP - 957

EP - 965

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

SN - 0022-1899

IS - 6

ER -